Incyte Corporation $INCY Holdings Boosted by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS raised its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 41.5% during the 3rd quarter, Holdings Channel reports. The fund owned 186,305 shares of the biopharmaceutical company’s stock after purchasing an additional 54,600 shares during the period. KLP Kapitalforvaltning AS’s holdings in Incyte were worth $15,801,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Cerity Partners LLC raised its stake in shares of Incyte by 23.6% during the third quarter. Cerity Partners LLC now owns 203,000 shares of the biopharmaceutical company’s stock valued at $17,216,000 after purchasing an additional 38,736 shares in the last quarter. CoreCap Advisors LLC acquired a new position in shares of Incyte in the 3rd quarter worth approximately $402,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Incyte by 4.3% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 45,584 shares of the biopharmaceutical company’s stock worth $3,866,000 after buying an additional 1,892 shares in the last quarter. D.A. Davidson & CO. purchased a new stake in shares of Incyte in the 3rd quarter valued at approximately $204,000. Finally, CWA Asset Management Group LLC acquired a new position in Incyte in the 3rd quarter worth approximately $5,954,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Royal Bank Of Canada upped their price target on Incyte from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Mizuho set a $121.00 price objective on Incyte and gave the company an “outperform” rating in a research report on Monday, December 8th. Piper Sandler upped their price target on shares of Incyte from $82.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Truist Financial set a $103.00 price target on Incyte in a research note on Wednesday, December 24th. Finally, Wells Fargo & Company lifted their price target on shares of Incyte from $97.00 to $116.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $99.53.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Phase‑3 frontMIND success in first‑line high‑risk DLBCL — reported results drove earlier upside by substantially raising the approval and commercial potential for tafasitamab in a front‑line setting, a major positive for long‑term revenue prospects. Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL
• Positive Sentiment: Positive top‑line Phase‑III results for tafasitamab (DLBCL) — reinforces the clinical case and regulatory/commercial runway for the drug program. This is a direct catalyst for valuation re‑rating. Positive top-line results for Incyte’s tafasitamab in DLBCL
• Positive Sentiment: Bullish analyst commentary — Morgan Stanley projects strong price appreciation and Barclays initiated/maintained a buy, supporting investor interest and providing near‑term demand from institutional buyers. Morgan Stanley Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock Incyte (INCY) Gets a Buy from Barclays
• Neutral Sentiment: INCB123667 completed Phase‑1 (early safety) — an important de‑risking step but still early; positive for pipeline breadth but limited immediate revenue impact. Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
• Neutral Sentiment: Broader analyst coverage and stock‑screen features — additional attention (The Globe and Mail, Zacks) can boost liquidity/interest but does not by itself change fundamentals. Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Incyte (INCY) Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Patient/therapy coverage (chronic GVHD story) highlights real‑world benefit of treatments in Incyte’s therapeutic areas, which supports long‑term product adoption but is not an immediate earnings catalyst. How a Chronic GVHD Treatment Is Helping Patients Stay One Step Ahead
• Negative Sentiment: Insider selling by EVP Mohamed Khairie Issa — sale of ~10,856 shares (filed with the SEC) may be read as executive profit‑taking and can weigh on sentiment, especially on a day with mixed newsflow. SEC Filing — Insider Sale
• Negative Sentiment: Competitor/market developments: Monjuvi (tafasitamab/combination data) being added to chemo regimens strengthens class evidence but could also shift competitive dynamics and reimbursement conversations — a mixed-to-negative near‑term read depending on commercialization details. Monjuvi Added to Standard Chemotherapy Improves Outcomes in Lymphoma

Incyte Price Performance

INCY opened at $105.92 on Friday. Incyte Corporation has a twelve month low of $53.56 and a twelve month high of $112.29. The company has a market capitalization of $20.79 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 0.67 and a beta of 0.82. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $101.84 and a 200-day moving average price of $87.82.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the previous year, the firm earned $1.07 EPS. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. Equities analysts expect that Incyte Corporation will post 4.86 EPS for the current year.

Insider Activity at Incyte

In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the completion of the transaction, the executive vice president owned 63,129 shares of the company’s stock, valued at approximately $6,471,353.79. This trade represents a 24.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael James Morrissey sold 54,008 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the completion of the transaction, the executive vice president owned 31,830 shares in the company, valued at $3,096,740.70. The trade was a 62.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 99,174 shares of company stock worth $9,892,957 over the last 90 days. 17.80% of the stock is owned by insiders.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.